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Abstract: Atrial fibrillation (AF) places a considerable burden on the US health care system, 
society, and individual patients due to its associated morbidity, mortality, and reduced health-
related quality of life. AF increases the risk of stroke, which often results in lengthy hospital 
stays, increased disability, and long-term care, all of which impact medical costs. An expected 
increase in the prevalence of AF and incidence of AF-related stroke underscores the need for 
optimal management of this disorder. Although AF treatment strategies have been proven 
effective in clinical trials, data show that patients still receive suboptimal treatment. Adherence 
to AF treatment guidelines will help to optimize treatment and reduce costs due to AF-associated 
events; new treatments for AF show promise for future reductions in disease and cost burden 
due to improved tolerability profiles. Additional research is necessary to compare treatment 
costs and outcomes of new versus existing agents; an immediate effort to optimize treatment 
based on existing evidence and guidelines is critical to reducing the burden of AF.
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Introduction
Atrial fibrillation (AF), the ineffective and uncoordinated contraction of the atria, is 
the most common sustained heart rhythm disturbance seen in clinical practice.1,2 An 
estimated 3.03 million Americans had AF in 2005, and the prevalence is expected to 
rise to 7.56 million by 2050.3 Between 1985 and 1999, the number of hospitalizations 
with AF as a principal diagnosis increased by 144% according to the National   Hospital 
Discharge Survey.4 These numbers are probably even greater, since arrhythmias 
represented 10.6% of patients with a principal diagnosis related to the circulatory 
system.5 Research demonstrates a potential link between AF and atherosclerotic 
vascular disease, hypertension, chronic inflammation, and metabolic syndrome.6 AF 
is also associated with substantial morbidity (stroke, heart failure), mortality, and poor 
health-related quality of life.7–14 Based on these issues, AF imposes a considerable cost 
burden on the patient, the health care system, and society.15–17
AF treatment is complex. Comprehensive management of the patient with AF requires 
a multifaceted approach directed at first identifying any underlying, reversible, treatable 
causes,18 and then controlling symptoms and protecting the patient from central and 
peripheral embolism.19,20 The American College of Cardiology Foundation, American 
Heart Association, and Heart Rhythm Society (ACCF/AHA/HRS) task force recommend 
that AF management involve three nonmutually exclusive objectives: rate control, 
prevention of thromboembolism, and correction of the rhythm disturbance (Figure 1).19 
The initial management decision is either a rate-control or rhythm-control strategy. 
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Using the rate-control strategy, the ventricular rate is controlled 
with no commitment to restore or maintain sinus rhythm, unlike 
the rhythm-control strategy, which attempts restoration and 
maintenance of sinus rhythm.19
Anticoagulation therapy is to be considered regardless of 
which rate or rhythm control therapy is prescribed, because 
current agents used for rate and rhythm control do not reduce 
stroke risk and cannot be substituted for antithrombotic 
treatment.21,22 The CHADS2 scoring system, which utilizes 
age and comorbid conditions to stratify a patient’s stroke risk, 
is recommended to aid in the decision to use antithrombotic 
therapy (Table 1).19,23 Despite the guidelines, AF may be 
managed suboptimally due to the complexity of treatment. 
It has been shown that compliance with some antiarrhythmic 
agents is poor and patients who discontinue treatment are 
unlikely to restart therapy.24 Suboptimal management of AF 
could result in a delay in reverting the patient to normal sinus 
rhythm, which in turn could promote atrial remodeling, mak-
ing future sinus rhythm maintenance difficult.25 This article 
discusses the clinical consequences and associated costs of 
suboptimal management of AF in the United States (US), as 
well as treatment strategies that may reduce the burden of 
AF and improve patient outcomes.
Overall economic burden  
of AF in the US
Although there are numerous cost-comparison studies of 
different AF treatments, there are few US-based direct cost 
assessments of AF treatments. A recent national survey 
estimated that direct medical costs were 73% higher in 
patients with AF compared with matched control subjects, 
representing a net incremental cost of $8705 per patient 
per year and a national incremental cost between $6.0 and 
$26.0 billion (2008 US dollars [USD]).26 A 2001 study 
found that approximately 234,000 hospital outpatient 
department visits, 276,000 emergency room visits, 
350,000 hospitalizations, and 5 million office visits were 
attributable annually to AF.15 It has been shown that in the 
year following index hospitalization, 12.5% of chronic AF 
patients and 10.1% of newly diagnosed AF patients are 
readmitted for AF.27 The total annual medical cost for the 
treatment of AF in the inpatient, emergency department, and 
hospital outpatient settings was estimated at $6.65 billion 
(2005 USD; inflation-adjusted to 7.71 billion 2011 USD) 
(Figure 2), and is likely an underestimate as costs for long-
term anticoagulation, stroke prevention, inpatient drugs, 
and hospital-based physician services were not included.15 
This assessment included billed hospital charges and costs 
of procedures for which AF was the principal discharge 
diagnosis ($2.93 billion), incremental inpatient costs due to 
AF as a comorbid diagnosis ($1.95 billion), and physician 
fees, drugs, procedures, and facility costs for ambulatory/
outpatient treatment of AF ($1.76 billion).15
Atenolol, amiodarone,
digoxin, diltiazem,
esmolol, metoprolol,
propranolol,
verapamil
Amiodarone,
disopyramide, dofetilide,
dronedarone, flecainide,
propafenone, sotalol
Aspirin, vitamin-K
antagonists (warfarin)
Anticoagulation
Rhythm
control
Rate
control
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(unless
 contraindicated)
Figure 1 AF treatment. Drugs are listed alphabetically.19 
Abbreviation: AF, atrial fibrillation.
Table 1 CHADS2 index stroke risk in patients with nonvalvular 
AF  not  treated  with  anticoagulation  and  recommended 
antithrombotic therapy by risk factorsa
CHADS2 risk criteria Score
Prior stroke or TIA 2
Age . 75 years 1
Hypertension 1
Diabetes mellitus 1
Heart failure 1
Risk categoryb Recommended therapy
No risk factors Aspirin, 81 to 325 mg daily
1 moderate risk factor Aspirin, 81 to 325 mg daily, or warfarin 
(INR 2.0 to 3.0, target 2.5)
Any high risk factor or .1 
moderate risk factor
Warfarin (INR 2.0 to 3.0, target 2.5)
Notes:  aGuideline-based  therapy  recommendations  include  consideration  of 
CHADS2 and other risk factors;  bmoderate risk factors: all CHADS2 risk factors 
with a score of 1 as well as left ventricular ejection fraction # 35%; high risk factors: 
prior stroke, TIA, or embolism; mitral stenosis; prosthetic heart valve (if mechanical 
valve, target INR . 2.5). 
Copyright© 2011, Elsevier. Adapted with permission from Fuster V, Ryden LE, Cannom 
DS, et al. 2011 ACCF/AHA/HRS Focused Updates Incorporated Into the ACC/AHA/
ESC 2006 Guidelines for the Management of Patients With Atrial Fibrillation A Report 
of the American College of Cardiology Foundation/American Heart Association Task 
Force on Practice Guidelines Developed in partnership with the European Society of 
Cardiology and in collaboration with the European Heart Rhythm Association and 
the Heart Rhythm Society. J Am Coll Cardiol. 2011;57(11):e101–e198.19
Abbreviations: TIA, transient ischemic attack; INR, international normalized ratio.
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One study estimated the direct and indirect costs of 
AF (2002 USD) in a privately insured US population 
aged ,65 years. The direct annual cost of AF was $15,553 
per patient compared with $3204 for enrollees without AF. 
These costs were adjusted to $19,575 and $4809 in 2011 
USD.16 Indirect costs (ie, disability claims and absenteeism) 
were $2134 higher annually for AF patients compared 
with enrollees without AF ($2847 [$3583 2011 USD] vs 
$713 [$897 2011 USD], respectively). Regarding patients 
aged .65 years, a Medicare database study found that 
the adjusted mean incremental treatment cost of AF was 
$14,199 (2004 USD; $17,019 2011 USD) in patients diag-
nosed with AF and followed for 1 year.17 Some of this cost 
was attributable to the incidence of stroke and heart failure 
1 year after diagnosis.17 In another study, inpatient costs were 
$11,307 (2006 USD; $12,699 2011 USD) and   outpatient 
costs were $2827 ($3175 2011 USD) for primary AF 
  hospitalization; for hospitalized patients with   secondary AF, 
AF-related inpatient costs were $5181 ($5819 2011 USD) and 
outpatient costs were $1376 ($1545 2011 USD).28 Table 2 
contains recently published data on direct health care costs 
attributable to an AF diagnosis, including cost   adjustments 
to 2011 USD (differing costs may reflect variations in study 
designs and data sets).28–30
Inpatient drug initiation and costs of adverse events and 
adverse-event monitoring significantly add to the overall 
  economic burden of AF treatment. A recent analysis   examined 
the costs associated with initiating sotalol and dofetilide in 
the inpatient setting.31 Treatment guidelines   recommend 
  inpatient initiation of dofetilide, while the   initiation of 
sotalol is   mandated by the US Food and Drug Administration 
(FDA), with a recommended minimum   hospital stay of 3 days 
to assess for ventricular proarrhythmia.19,32,33 Mean total 
  inpatient costs per patient were $3278 in the sotalol group 
and $3610 in the dofetilide group (2007 USD; $3580 and 
$3942 2011 USD, respectively). The greatest costs were for 
room and board followed by cardiology/electrocardiograms.31 
The incidence and cost of suspected adverse events and 
adverse-event monitoring during AF rhythm control and/or 
rate-control therapy was also high.34 Overall, 50.1% of treated 
patients had a suspected adverse event and/or function test for 
adverse-event monitoring (45.5% with rate control, 53.5% 
with rhythm control, and 61.2% with combined rhythm/rate 
control). The mean cost of adverse events and adverse-event 
monitoring among treated patients was $3089 per patient 
(2006 USD; $3469 2011 USD).34
Cost of stroke in patients with AF
Stroke is a leading cause of death in the world and a 
leading cause of morbidity in adults aged .60 years.35 
Outpatient, 23%
Direct inpatient, 44%
Indirect inpatient, 29%
Drugs, 4%
Figure 2 Distribution of total medical costs for treating AF in the United States 
(2005). 
Copyright© 2006, John Wiley and Sons. Reprinted with permission from Coyne KS, 
Paramore C, Grandy S, Mercader M, Reynolds M, Zimetbaum P. Assessing the direct 
costs of treating nonvalvular atrial fibrillation in the United States. Value Health. 
2006;9(5):348–356.15
Abbreviation: AF, atrial fibrillation.
Table 2 Recently published AF health care costs
Study  
(USD)
Diagnosis Patient population Inpatient  
costsa
Outpatient  
costsa
Total AF-related   
costsa
Patel29 
(2006 USD)
Nontransient  
AF/AFL
32,905 patients in US claims database  
(mean age 74 years, 56% male, 1/04–12/07)
$22,582 ($25,362) $15,688 ($17,620) $38,270 ($42,982)
Kim28 
(2006 USD)
Primary AF 35,255 patients in US claims database  
(mean age 64 years, 65% male, 1/05–12/06)
$11,307 ($12,699) $2827 ($3175) $14,134 ($15,874)
Secondary AF $5181 ($5819) $1376 ($1545) $6557 ($7364)
Kim30 
(2007 USD)
AF 3605 patients in US claims database  
(mean age 63 years, 69% male, 4/01–3/07)
$3872 ($4228) $2293 ($2504) $6165 ($6732)
Note: aCosts inflation-adjusted to 2011 USD using the Bureau of Labor Statistics CPI inflation calculator. 
Abbreviations: AF, atrial fibrillation; AFL, atrial flutter; USD, United States dollars.
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AF independently increases the risk of ischemic stroke by 
four- to fivefold.36 In the absence of antithrombotic therapy, 
the annual risk of stroke in patients with AF (with risk fac-
tors including history of hypertension, diabetes, and history 
of prior stroke/transient ischemic attack [TIA]) is 4.9% in 
patients aged ,65 years and 8.1% in patients aged .75 years.37 
Because the prevalence of AF increases with age and older age 
confers an increased risk of stroke, the proportion of strokes 
attributable to AF increases with age.37
Stroke is associated with substantial inpatient and long-
term costs.38 A review of published data on AF prevalence 
found that survivors of AF-related stroke were more likely 
to have longer hospital stays, disability, and need for long-
term care, all of which increase health care costs.39 A review 
of 14 studies found that patients with AF-related stroke had 
worse outcomes than patients with non-AF-related stroke, 
including higher mortality, severity, recurrence, functional 
impairment, and dependency.40 A retrospective chart review 
showed that patients with AF-associated ischemic stroke 
were 2.23 times more likely to be bedridden than patients 
who had strokes from other causes.41 Importantly, previously 
diagnosed AF patients in this chart review were not receiving 
therapeutic anticoagulation at the time of their stroke.41
A recent retrospective observational cohort study 
  utilized medical and pharmacy claims from a managed 
care organization to identify continuously benefit-eligible 
AF patients without prior valvular disease or warfarin use 
between 2000 and 2002 (costs adjusted to 2004 USD).42 
All patients were followed for at least 6 months, until plan 
termination or the end of study follow-up. Stroke risk was 
assessed using the CHADS2 index. Inpatient and outpa-
tient cost benchmarks were utilized to estimate total direct 
health care costs (pre- and post-AF index claim). Total direct 
health care costs were also assessed for patients with TIA, 
ischemic stroke (IS), and major bleed (MB). Pre- versus 
post-AF diagnosis total direct health care costs were $412 and 
$1235 per member per month (pmpm), respectively ($494 and 
$1480 2011 USD, respectively). Of the 448 (12%) patients 
with a TIA, IS, or MB, pmpm costs post-AF diagnosis ranged 
from $2235 to $3135 ($2679–$3758 2011 USD) correlating 
with CHADS2 stroke-risk status and exposure to warfarin. 
Total cohort pmpm costs pre- and post-event increased 24% 
from $3447 to $4262 ($4132–$5109 2011 USD).42
Cost benefits of optimal 
anticoagulation
In the US, increasing rates of AF-related stroke due to the 
aging population will come at a high cost to society given 
the overlap between AF-attributable stroke and the age of 
Medicare eligibility. The need for optimal anticoagulation 
was demonstrated in a pooled analysis of five large, 
randomized, controlled AF antithrombotic trials, which 
showed that warfarin reduced the frequency of all strokes by 
68% (95% confidence interval [CI]: 50%–79%); the efficacy 
of aspirin was less consistent.37 A conservative economic 
model estimated a Medicare saving of $1.14 billion annually 
(2003 USD; $1.4 billion 2011 USD) through maintaining 
patients eligible for anticoagulation on therapeutic doses of 
warfarin.43 Depending on the study population, anticoagulant 
therapy has been shown to decrease the risk of stroke by 
42% to 86%.44
Although several randomized clinical trials have 
  documented the benefits of warfarin in preventing 
  AF-related stroke, a growing body of evidence indicates 
that   anticoagulants are routinely underutilized for stroke 
prevention in patients with AF.45,46 It has been estimated that 
half of the patients receiving warfarin do not receive the 
appropriate   anticoagulant therapy.44 Anticoagulant therapy 
with   warfarin has a   narrow therapeutic index requiring 
coagulation monitoring by a physician or, in some cases, 
pharmacists and nurses;47,48 this requirement, along with the 
inherent properties of warfarin related to its bleeding risk, 
may contribute to its low levels of utilization.45 A comparative 
study between usual medical care and a clinical pharmacist-
run anticoagulation clinic showed that pharmacist supervi-
sion improved   anticoagulation control, reduced bleeding 
and thromboembolic event rates, and saved $162,058 per 
100 patients annually (1998 USD; $225,112 2011 USD) in 
reduced hospitalizations and   emergency   department visits.49 
Figure 3 presents a disease model showing the effects of 
  suboptimal versus optimal oral   anticoagulation on stroke 
rates. The economic model considers a stable   population of 
patients with AF, such as that which might be found in a man-
aged care organization or a state’s Medicare group; it allows 
for movement of individuals with AF in and out of the popula-
tion during the course of a year. Scenarios are created (eg, “if 
half of all those who currently do not receive anticoagulation 
were to receive well-controlled warfarin”) to represent the 
current situation in the population of interest compared with 
other potential scenarios of care. According to this model, 
stroke rates and associated costs could decrease dramatically 
if 50% of warfarin-eligible patients were   optimally coagu-
lated. Approximately 1.265 million patients currently not 
receiving prophylaxis suffer over 58,000 strokes annually. If 
half of those not receiving warfarin were optimally anticoagu-
lated, approximately 19,000 strokes would be prevented.43
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Figure 3 Model results: (A) reductions in AF-related stroke based upon half of 
untreated patients receiving warfarin and (B) cost of stroke.43 The economic model 
considers a stable population of patients with AF, such as that which might be found 
in a managed care organization or a state’s Medicare group.
Notes:  Cost  estimates  were  based  on  published  epidemiologic  data  and  2003 
Medicare cost data. Values in parentheses are inflation-adjusted costs to 2011 US 
dollars using the Bureau of Labor Statistics CPI inflation calculator. 
Abbreviation: AF, atrial fibrillation.
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Warfarin therapy is monitored to ensure that patients 
remain within the target international normalized ratio (INR) 
range of 2.0 to 3.0. Studies of the quality of anticoagulation 
management in patients with AF found that up to 60% of 
patients receiving warfarin have INR outside the recommended 
therapeutic target range.50–52 It is likely that these studies can 
be generalized to the US population as they included AF 
patients in a range of settings (emergency department, long-
term care, and community); one can therefore conclude that 
the majority of patients with an AF diagnosis in the US are 
not optimally treated with anticoagulant therapies. Such 
suboptimal therapy places patients at risk for complications 
and further management expenditures.53
One real-world study estimated the cost effectiveness 
of different warfarin treatment scenarios.53 A semi-Markov 
transition model (11 primary health states with four additional 
states representing temporary discontinuation of therapy) was 
designed due to the chronic nature of AF and its treatment 
and the varying but continuous risk of stroke and hemorrhage. 
The scenarios included in the model were: (1) perfect   warfarin 
  control (100% of patients within target INR and following 
guideline recommendations19,54 for ideal treatment goal); 
(2) trial-like warfarin control (clinical trial conditions; INRs 
within target 68% of the time as reported in the Stroke 
P  revention by ORal Thrombin Inhibitor in atrial Fibrillation 
  [SPORTIF] V trial);55 (3) “real-world” warfarin control (r  outine 
clinical practice conditions; INRs within   target 48% of the 
time based on data from a retrospective study of US outpatient 
physician practices);56 and (4) real-world   prescription (and 
control) of warfarin, aspirin, or neither for warfarin-  eligible 
patients at moderate-to-high risk of stroke (routine clinical 
practice conditions, in which a proportion of warfarin-eligible 
patients were prescribed either aspirin [12%] or neither war-
farin nor aspirin [23%]).56 The total number of primary and 
recurrent ischemic strokes in a cohort of 1000 patients (age 70 
years) was assessed, and the model showed increased numbers 
of strokes as real-world conditions increased and trial-like 
management declined. Both clinical and cost outcomes were 
found to be dependent on the quality of anticoagulation 
(Table 3).
In another cost-effectiveness semi-Markov decision 
analysis model of patients with AF, the lifetime cost per 
patient for anticoagulation using a monitoring service was 
found to be $8661 versus $10,746 for usual care (2004 USD; 
$10,381 vs $12,880 2011 USD).57 The model predicted 
that anticoagulation services improved the effectiveness 
(measured in quality-adjusted life-years [QALYs]) and 
reduced costs (estimated at $2100; $2517 2011 USD), and 
was therefore superior to usual care.
In terms of the cost of MB events with warfarin use, 
a recent database study of warfarin-treated patients with 
AF found that MB events associated with warfarin therapy, 
although nearly twice as costly compared with patients 
without MB events, were relatively rare; among 47,437 total 
patients, only 194 (0.4%) had intracranial MB events and 
919 (1.9%) experienced gastrointestinal MB events.58
In addition to warfarin and other anticoagulants (eg, 
unfractionated heparin and low-molecular-weight   heparin), 
direct thrombin inhibitors represent a newer class of 
anticoagulants.59 Newer antithrombotic agents include 
rivaroxaban, apixaban, and dabigatran, which are   selective 
for specific coagulation factors such as factor Xa and throm-
bin.60–62 Advantages shared by these newer   anticoagulants 
over existing antithrombotic agents consist of selective 
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targeting for a single coagulation factor, rapid onset of action, 
fewer drug interactions, and no required dosage adjustment 
according to patient age, gender, body weight, or mild renal 
impairment.62 Clinical trials with these new   anticoagulants 
in patients with AF include ROCKET-AF (rivaroxaban vs 
  warfarin), ARISTOTLE (apixaban vs warfarin) and AVER-
ROES (apixaban vs aspirin in patients unsuitable for war-
farin). The ROCKET-AF trial showed that rivaroxaban was 
noninferior to warfarin with regard to stroke or systemic 
embolism in patients with nonvalvular AF.63 Rivaroxaban is 
approved by the FDA for the prevention of stroke in patients 
with nonvalvular AF.64 In the   AVERROES study, apixaban 
reduced the risk of stroke or systemic embolism without 
significantly increasing major bleeding or intracranial hem-
orrhage,65 while the ARISTOTLE study demonstrated that 
apixaban was superior to warfarin in preventing stroke or 
systemic embolism.66 An important limitation to the use of 
these agents is the lack of readily available reversal agents 
or antidotes.
Dabigatran is a novel oral direct thrombin inhibitor that 
is approved in the US (October 2010) to reduce the risk of 
stroke and systemic embolism in patients with AF.67 In the 
Randomized Evaluation of Long-Term Anticoagulation 
Therapy (RE-LY) trial, two fixed doses of dabigatran 
(110 and 150 mg, administered in a blinded fashion) were 
compared with open-label use of warfarin in patients with 
AF and an increased risk for stroke.68,69 After a follow-up of 
2 years, the primary endpoint of stroke or systemic embolism 
occurred in 182 patients in the dabigatran 110 mg group 
(1.53%/year), 134 patients in the dabigatran 150 mg group 
(1.11%/year), and 199 patients in the warfarin group (1.69%/
year). Both dabigatran doses were found to be noninferior to 
warfarin (P , 0.001), and the dabigatran 150-mg dose was 
found to be superior to warfarin (P , 0.001). Hemorrhagic 
stroke rates were 0.38% per year in the warfarin group 
versus 0.12% per year in the dabigatran 110 mg group and 
0.10% per year in the dabigatran 150 mg group (P , 0.001, 
both comparisons). This decrease in the number of strokes 
with dabigatran may decrease the costs and economic burden 
associated with stroke. The 2011 ACCF/AHA/HRS guide-
lines recommend dabigatran as an alternative to warfarin 
for the prevention of stroke and systemic thromboembolism 
in patients who have paroxysmal to permanent AF and risk 
factors for stroke/systemic embolization and who do not have 
a prosthetic heart valve, hemodynamically significant valve 
disease, severe renal failure, or advanced liver disease.70
Cost effectiveness of treatment 
strategies for AF
The Fibrillation Registry Assessing Costs, Therapies, 
Adverse Events, and Lifestyle (FRACTAL) study showed 
that patients with AF who are managed with cardioversion 
and pharmacotherapy incur AF- and cardiovascular-
related health care costs of $4000 to $5000 per year (2002 
USD; $5034–$6293 2011 USD).71 AF-related health care 
costs averaged $4700 ($5915 2011 USD) per patient per 
year during the first few years following diagnosis,71 but 
subsequent annual costs varied greatly according to the 
AF clinical course, with hospital care contributing the 
largest and most variable component of total cost. Among 
patients with recurrent AF, the frequency of recurrence 
was strongly associated with higher resource utilization, 
with each recurrence increasing annual costs by an average 
of $1600 (2002 USD; $2014 2011 USD).71 Several recent 
studies comparing rate and rhythm control strategies have 
found no meaningful differences in terms of mortality from 
cardiovascular causes and stroke.8,21,72–75 Additionally, drivers 
of cost in patients with AF are not fully elucidated.
A post-hoc cost-effectiveness analysis from the Atrial 
Fibrillation Follow-Up Investigation of Rhythm Management 
(AFFIRM) study was published shortly after the FRACTAL 
study and demonstrated that patients randomized to 
pharmacologic rate control had less resource utilization 
and lower costs than patients randomized to rhythm control 
Table  3  Results  of  a  cost-effectiveness  model  predicting  clinical  trial  versus “real-world”  warfarin  usage  for AF-related  stroke 
prevention53
Base casea:  
total medical costs/patient  
(2006 USD/2011 USDb)
Base case:  
total # primary and  
recurrent IS
Modelc: 
total # primary  
and recurrent IS
Scenario 1: perfect warfarin control $68,039/$76,416 626 503
Scenario 2: clinical trial-like warfarin control $77,764/$87,338 832 737
Scenario 3: real-world warfarin control $84,518/$94,924 984 909
Scenario 4: real-world warfarin, aspirin, or neither $87,248/$97,990 1171 1120
Notes: aBase case: N = 1000, age 70, moderate-to-high risk of stroke, followed for remaining lifetime; bcosts inflation-adjusted to 2011 USD using the Bureau of Labor 
Statistics CPI inflation calculator; cperfect warfarin adherence. 
Abbreviations: IS, ischemic stroke; USD, United States dollars.
submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
84
SinghClinico Economics and Outcomes Research 2012:4
(cost savings range, $2189–$5481 per patient, 2002 USD; 
$2755–$6898 2011 USD).76 Another post-hoc analysis of 
AFFIRM clinical treatment data suggested that the benefits 
of rhythm control may have been offset by the adverse 
effects of antiarrhythmic therapy, specifically amiodarone, 
which was used for rhythm control in the study.77 Whether 
these AFFIRM cost data would be affected if different 
antiarrhythmic agents (with better adverse-effect profiles 
than amiodarone) were analyzed in the model is unknown; 
however, as the adverse effects had considerable influence 
over the cost model, cost data can be expected to be 
affected.77
Newer anticoagulants and antiarrhythmic agents may 
present cost savings compared with older treatments. In an 
analysis including patients aged $65 years with AF who 
were at increased risk of stroke, dabigatran was shown to 
be a cost-effective alternative to warfarin.78 The analysis 
estimated a cost of $45,372 per QALY (2008 USD; $47,715 
2011 USD) gained with high-dose dabigatran (150 mg twice 
daily) compared with warfarin.78 Another study compared 
the cost-effectiveness of dabigatran 150 mg twice daily 
with warfarin, employing a Markov decision-analysis 
model in a hypothetical cohort of 70-year-old patients with 
AF and a cost-effectiveness threshold of $50,000/QALY.79 
The analysis found dabigatran to be cost-effective in AF 
populations at high risk of hemorrhage or stroke (CHADS2 
score $ 3) and warfarin to be cost-effective in moderate-risk 
AF populations (CHADS2 score 1 or 2). Dabigatran was 
cost-effective for patients with a CHADS2 score of 2 only 
if they were at a high risk of major hemorrhage or had poor 
INR control with warfarin.79 In a separate cost-effectiveness 
analysis employing a Markov decision-analysis model in a 
hypothetical cohort of 70-year-old patients with AF and a 
history of stroke or transient ischemic attack, dabigatran 
provided 0.36 additional QALYs versus warfarin at a cost 
of $9000 (2010 USD; $9314 2011 USD), yielding an 
incremental cost-effectiveness ratio of $25,000 ($25,873 
2011 USD). However, dabigatran was not cost-effective if 
its relative risk of stroke compared with warfarin exceeded 
0.92.80 Lastly, in a cost-effectiveness analysis in the United 
Kingdom of simulated patients at moderate-to-high risk of 
stroke with a mean baseline CHADS2 score of 2, dabigatran 
150 mg twice daily was associated with positive incremental 
net benefits versus warfarin, but was unlikely to be cost-
effective in clinics able to achieve good INR control with 
warfarin.81
Given the 24% relative reduction in hospitalizations 
demonstrated with dronedarone use in the A Placebo-Controlled, 
Double-Blind, Parallel Arm Trial to Assess the Efficacy of 
Dronedarone 400 mg bid for the Prevention of Cardiovascular 
Hospitalization or Death from any Cause in Patients with Atrial 
Fibrillation/Atrial Flutter (ATHENA) trial,82 this agent has the 
potential to reduce costs in patients with AF. One retrospective 
study analyzed the incidence and direct costs of ATHENA-
type outcomes in 15,552 patients with AF who were covered 
by Medicare supplemental insurance from 2004 to 2007.83 
Mean hospitalization cost per patient was $11,085 (2006 
USD; $12,450 2011 USD). Mean costs per patient varied from 
$7476 (mean cost per hospitalization for AF/supraventricular 
rhythm disorder [primary diagnosis, nonfatal]) to $37,067 
(mean hospitalization cost per death, cardiovascular 
transcutaneous intervention procedure, or cardiovascular 
surgical intervention) ($8396 to $41,631, respectively, 2011 
USD).83 Novel antiarrhythmic therapies such as dronedarone, 
with the potential to reduce cardiovascular hospitalizations 
and mortality in similar patients, could decrease health 
care costs.
New antiarrhythmic agents  
for the treatment of AF
Data demonstrate limited efficacy and partially deleterious 
adverse-effect profiles for conventional antiarrhythmic agents 
for AF.84 Antiarrhythmic agents that have atrial-selective 
actions and target multiple ion channels may be more 
tolerable and free of proarrhythmic effects.85 New agents 
(ie, dronedarone and vernakalant) offer promise in optimizing 
the management of AF by potentially reducing AF burden 
and costs through more favorable tolerability profiles.
Dronedarone
Dronedarone, a noniodinated benzofuran derivative, is 
a recently (2009) approved multichannel antiarrhythmic 
agent. Dronedarone is indicated in the US to reduce the 
risk of hospitalization for AF in patients in sinus rhythm 
with a history of paroxysmal or persistent AF.86 According 
to the 2011 ACCF/AHA/HRS guidelines, dronedarone is 
recommended as first-line therapy in patients with AF who 
have no or minimal heart disease, hypertension without left 
ventricular hypertrophy, or coronary heart disease (class 
IIa recommendation).70 In the ATHENA trial, dronedarone 
demonstrated a significant risk reduction (24%, P , 0.001) 
in hospitalizations due to cardiovascular events or deaths 
from any cause compared with placebo in patients with 
paroxysmal or persistent AF/AFL.82 In an analysis of stroke 
in the ATHENA trial, dronedarone reduced the risk of 
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stroke from 1.8% per year to 1.2% per year (P = 0.027).87 In 
the Efficacy and Safety of Dronedarone for the Control of 
Ventricular Rate During Atrial Fibrillation (ERATO) study, 
dronedarone was found to control ventricular rate in patients 
diagnosed with permanent AF already treated with standard 
therapies.88
Dronedarone was demonstrated to be effective in 
maintaining sinus rhythm in The European Trial in Atrial 
  Fibrillation or Flutter Patients Receiving Dronedarone for 
the Maintenance of Sinus Rhythm (EURIDIS) study and 
the American–  Australian–African Trial with Dronedarone 
in Atrial Fibrillation or Flutter Patients for the Maintenance 
of Sinus Rhythm (ADONIS) study.89 The most common 
adverse events seen with dronedarone include gastrointestinal 
problems including diarrhea, nausea, and abdominal pain.82,88–
91   Dronedarone is contraindicated in patients with symp-
tomatic heart failure with recent decompensation requiring 
hospitalization or New York Heart Association (NYHA) class 
IV heart failure and in patients with AF who will not or can-
not be cardioverted into normal sinus rhythm.86
The PALLAS study, a trial assessing potential   cardiovascular 
outcomes in patients with permanent AF, was   prematurely 
terminated due to increased adverse   cardiovascular events in 
the dronedarone arm.92 There were 25 deaths in the drone-
darone group (21 from cardiovascular causes) and 13 in the 
placebo group (10 from cardiovascular causes) (P = 0.046). 
The coprimary outcome, a composite of stroke, myocardial 
infarction, systemic embolism, or death from cardiovascular 
causes, occurred in 43 patients receiving dronedarone and 
19 patients receiving placebo (P = 0.002). These data indicate 
that dronedarone should not be used in patients with permanent 
AF who are at risk for major vascular events.92
There have been several postmarketing reports of 
hepatocellular liver injury and hepatic failure in patients 
receiving dronedarone, including two reports of acute 
hepatic failure that required transplantation and new-onset or 
worsening heart failure.93,94 Obtaining periodic hepatic serum 
enzymes, especially during the first 6 months of treatment 
with dronedarone, is recommended.86 Postmarketing cases 
of increased INR with or without bleeding events have 
also been reported in patients on warfarin initiated on 
dronedarone.86,95 Postmarketing cases of interstitial lung 
disease including pneumonitis and pulmonary fibrosis have 
also been reported.86 Exposure to dabigatran is also higher 
when it is administered with dronedarone than when it is 
administered alone.86
The US FDA recently completed a safety review of drone-
darone based on data from the PALLAS and ATHENA trials. 
This review showed that dronedarone increased the risk of 
serious cardiovascular events, including death, when used by 
patients with permanent AF.96 The prescribing information 
for dronedarone has been revised to include recommenda-
tions from the FDA regarding the use of dronedarone to 
manage the potential serious cardiovascular risks with the 
drug.86,96 These recommendations include: dronedarone 
should not be used in patients with AF who cannot or will 
not be converted into normal sinus rhythm (permanent AF); 
heart rate should be monitored by electrocardiogram at least 
once every 3 months, and if the patient is in AF, dronedarone 
should be stopped or, if clinically indicated, the patient should 
be cardioverted; dronedarone is indicated to reduce hospital-
ization for AF in patients in sinus rhythm with a history of 
nonpermanent AF (known as paroxysmal or persistent AF); 
and patients taking dronedarone should receive appropriate 
antithrombotic therapy.86,96
Vernakalant
Intravenous vernakalant, a sodium and potassium   channel 
blocker with atrial-selective action, is approved in the 
European Union, Iceland, and Norway for the rapid 
  conversion of recent-onset AF to sinus rhythm in adult 
  nonsurgery patients with AF of #7 days duration and for 
adult post-cardiac surgery patients with AF of #3 days 
duration.97 In the AVRO study, intravenous vernakalant 
was more effective than amiodarone for acute conversion of 
  recent-onset AF.98 For the oral formulation, early phase II 
  studies demonstrated that oral vernakalant successfully main-
tained sinus rhythm compared with placebo, and no proar-
rhythmias relating to vernakalant have been reported to date.99 
There were also no serious adverse events related to vernakal-
ant in phase II trials.100 Vernakalant was found to be an effec-
tive agent for conversion to normal sinus rhythm in patients 
with recent-onset AF.99 In a review of six early-phase clinical 
trials, vernakalant rapidly and effectively terminated recent-
onset AF and was found to be well tolerated and efficacious 
at AF conversion in patients with postoperative AF.99 Further 
studies are warranted to better define the role of vernakalant 
in the management of AF in order to determine whether its 
benefits translate into a decreased cost burden.
Catheter ablation
For AF patients whose symptoms are not well controlled 
with pharmacologic therapy, catheter ablation is an 
increasingly used treatment option. According to the 
2011ACCF/AHA/HRS guideline update, catheter ablation 
may be useful to maintain sinus rhythm in selected patients 
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with significantly symptomatic, paroxysmal AF who 
have failed treatment with an antiarrhythmic agent and 
have normal or mildly dilated left atria, normal or mildly 
reduced left ventricular function, and no severe pulmonary 
disease (class I recommendation upgraded from class IIa, 
but remaining a class IIa recommendation in both Europe 
and Canada); to treat symptomatic persistent AF (class IIa 
recommendation); and to treat symptomatic paroxysmal 
AF in patients with significant left atrial dilatation or 
with significant left ventricular dysfunction (class IIb 
recommendation).70 Recent studies have reported that 
catheter ablation successfully treats paroxysmal AF in .80% 
of cases and persistent AF in .70% of cases.101 However, 
catheter ablation is associated with major complications 
(reported in about 6% of procedures) such as pulmonary 
vein stenosis, thromboembolism, atrioesophageal fistula, 
and left atrial flutter.19,102
The cost-effectiveness of catheter ablation is difficult to 
determine due to a number of factors, including differences in 
the experience levels of centers, use of technology, and rates 
of reimbursement, which affect cost calculations.101 Studies 
evaluating the cost-effectiveness of AF ablation compared 
with rhythm control or antiarrhythmic agents have shown 
that ablation treatment results in improved quality-adjusted 
life expectancy, but at a higher cost.103–105
Conclusion
Recent data present a compelling picture of the burden of 
AF on the US health care system and society. As the US 
population ages and the prevalence of AF increases, it is 
clear that AF management strategies need to be optimal. 
Suboptimal management of AF places patients at risk for 
AF-associated stroke, the most costly AF-associated event. 
Numerous studies demonstrate the efficacy of anticoagulation 
in reducing the risk of AF-related embolic events and 
preventing hospitalizations, but efficacy is compromised by 
inadequate and suboptimal treatment patterns. Therapeutic 
strategies such as rate control, rhythm control, and 
anticoagulation provide cost-effective means to optimally 
manage the patient with AF, as do treatment options such as 
new antiarrhythmic agents or catheter ablation. Given that 
nearly 75% of the total costs associated with AF are attributed 
to direct and indirect hospitalization costs,15 clinical strategies 
that can reduce AF-related hospitalizations may optimize 
care by improving clinical outcomes and reducing costs. 
Further research is necessary to compare new antiarrhythmic 
agents with existing therapies to assess clinical and economic 
differences in real-world settings.
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